So here's a classic market scenario: a stock starts moving on rumors, the company says "not so fast," and everyone tries to figure out what's really going on. That's exactly what happened with Nanobiotix S.A. (NBTX) on Wednesday.
The cancer drug developer's shares were up more than 6% after the company responded to what it called "recent media speculation" about potential acquisition interest. The twist? Nanobiotix said there's no ongoing takeover process happening at all.
Earlier reports from French media outlet La Lettre had suggested Johnson & Johnson (JNJ) might be interested in the biotechnology firm. You can see why investors might get excited—when a pharmaceutical giant like J&J comes knocking, it usually means someone's technology is worth paying attention to.
The Official Word: No Process Here
In its statement, Nanobiotix didn't just say "no comment"—it went further. The company said it had "identified factual inaccuracies" in the media reports and made clear it "is not pursuing any control changes." That's corporate-speak for "we're not for sale, at least not right now."
Instead, the company says it's staying focused on what it does best: developing innovative cancer treatments using its proprietary nanotechnology. This isn't some early-stage biotech either—Nanobiotix is a late-stage clinical company with actual products in development.
Here's where things get interesting though: Nanobiotix and Johnson & Johnson already have a relationship. Back in 2023, they signed a global licensing, co-development, and commercialization agreement for NBTXR3, an investigational radioenhancer that could be first-in-class if it works. Then in 2025, they amended that agreement in a way that significantly reduced Nanobiotix's financial burden while setting up potential milestone payments for the smaller company.
So when rumors surface about J&J being interested in buying Nanobiotix outright, it's not completely out of left field. They're already partners. Sometimes partnerships turn into acquisitions, and sometimes they don't.
What the Charts Are Saying
Let's talk about the stock movement, because it's been quite a ride. Nanobiotix shares have skyrocketed 774.83% over the past 12 months. That's not a typo—nearly eight times your money in a year. Even with Wednesday's pop, the stock is trading 2.4% below its 20-day simple moving average but remains 18.5% above its 50-day SMA, showing longer-term strength.
The technical indicators tell a story of mixed momentum. The RSI sits at 47.95, which is neutral territory—not overbought, not oversold. But the MACD is at 1.0828, below its signal line at 1.9719, which suggests some bearish pressure in the near term.
For traders watching the levels:
- Key Resistance: $32.50
- Key Support: $30.00
The stock closed at $31.07 on Wednesday, right in the middle of that range.
The Bigger Picture
What's really happening here is a momentum story. When a stock is up 775% in a year, everything gets amplified—good news, bad news, and especially rumors. The company's statement seems designed to calm things down and refocus attention on its actual business: developing cancer treatments.
But here's the thing about takeover rumors: sometimes they start for a reason. Maybe someone at J&J mentioned Nanobiotix in a meeting. Maybe an analyst speculated about consolidation in the sector. Or maybe it's just the market connecting dots that aren't actually connected.
What we know for sure is that Nanobiotix has valuable technology, a big pharmaceutical partner, and a stock that's been on an absolute tear. Whether that adds up to an acquisition down the road is anyone's guess, but for now, the company says it's business as usual.
Sometimes the most interesting thing a company can say is "no"—especially when everyone was hoping for a "yes."
